171 related articles for article (PubMed ID: 35008775)
1. Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy.
He Y; Tian H; Dai C; Wen R; Li X; Webster KA; Li W
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008775
[TBL] [Abstract][Full Text] [Related]
2. Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety.
Tang F; LeBlanc ME; Wang W; Liang D; Chen P; Chou TH; Tian H; Li W
Angiogenesis; 2019 Aug; 22(3):369-382. PubMed ID: 30644010
[TBL] [Abstract][Full Text] [Related]
3. Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy.
Dai C; Waduge P; Ji L; Huang C; He Y; Tian H; Zuniga-Sanchez E; Bhatt A; Pang IH; Su G; Webster KA; Li W
Cell Mol Life Sci; 2022 Jan; 79(1):63. PubMed ID: 35006382
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Systemic Anti-Scg3 Therapy to Treat Oxygen-Induced Retinopathy.
Dai C; Tian H; Bhatt A; Su G; Webster KA; Li W
Front Biosci (Landmark Ed); 2022 Apr; 27(4):130. PubMed ID: 35468689
[TBL] [Abstract][Full Text] [Related]
5. Secretogranin III as a novel target for the therapy of choroidal neovascularization.
LeBlanc ME; Wang W; Ji Y; Tian H; Liu D; Zhang X; Li W
Exp Eye Res; 2019 Apr; 181():120-126. PubMed ID: 30633921
[TBL] [Abstract][Full Text] [Related]
6. Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization.
Ji L; Waduge P; Hao L; Kaur A; Wan W; Wu Y; Tian H; Zhang J; Webster KA; Li W
FASEB J; 2022 Jan; 36(1):e22106. PubMed ID: 34918375
[TBL] [Abstract][Full Text] [Related]
7. Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies.
Dai C; Webster KA; Bhatt A; Tian H; Su G; Li W
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062733
[TBL] [Abstract][Full Text] [Related]
8. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy.
LeBlanc ME; Wang W; Chen X; Caberoy NB; Guo F; Shen C; Ji Y; Tian H; Wang H; Chen R; Li W
J Exp Med; 2017 Apr; 214(4):1029-1047. PubMed ID: 28330905
[TBL] [Abstract][Full Text] [Related]
9. Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy.
Ji L; Waduge P; Wu Y; Huang C; Kaur A; Oliveira P; Tian H; Zhang J; Stout JT; Weng CY; Webster KA; Li W
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445707
[TBL] [Abstract][Full Text] [Related]
10. Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization.
Ji L; Waduge P; Wan W; Tian H; Li J; Zhang J; Chen R; Li W
FEBS J; 2022 Jun; 289(12):3521-3534. PubMed ID: 35038348
[TBL] [Abstract][Full Text] [Related]
11. Anti-Scg3 Gene Therapy to Treat Choroidal Neovascularization in Mice.
Huang C; Ji L; Kaur A; Tian H; Waduge P; Webster KA; Li W
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509549
[TBL] [Abstract][Full Text] [Related]
12. Secretogranin III: a diabetic retinopathy-selective angiogenic factor.
Li W; Webster KA; LeBlanc ME; Tian H
Cell Mol Life Sci; 2018 Feb; 75(4):635-647. PubMed ID: 28856381
[TBL] [Abstract][Full Text] [Related]
13. Neurovascular abnormalities in retinopathy of prematurity and emerging therapies.
Dai C; Xiao J; Wang C; Li W; Su G
J Mol Med (Berl); 2022 Jun; 100(6):817-828. PubMed ID: 35394143
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of neovascularization and expression shift of pro-/anti-angiogenic vascular endothelial growth factor isoforms after intravitreal bevacizumab injection in oxygen-induced-retinopathy mouse model.
Shi X; Zhao M; Xie WK; Liang JH; Miao YF; DU W; Li XX
Chin Med J (Engl); 2013 Jan; 126(2):345-52. PubMed ID: 23324288
[TBL] [Abstract][Full Text] [Related]
15. Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1α-VEGF pathway in oxygen-induced retinopathy mice.
Xu Y; Lu X; Hu Y; Yang B; Tsui CK; Yu S; Lu L; Liang X
J Pineal Res; 2018 May; 64(4):e12473. PubMed ID: 29411894
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease.
Wang W; LeBlanc ME; Chen X; Chen P; Ji Y; Brewer M; Tian H; Spring SR; Webster KA; Li W
Angiogenesis; 2017 Nov; 20(4):479-492. PubMed ID: 28447229
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of retinal neovascularization by a PEDF-derived nonapeptide in newborn mice subjected to oxygen-induced ischemic retinopathy.
Sheibani N; Zaitoun IS; Wang S; Darjatmoko SR; Suscha A; Song YS; Sorenson CM; Shifrin V; Albert DM; Melgar-Asensio I; Kandela I; Henkin J
Exp Eye Res; 2020 Jun; 195():108030. PubMed ID: 32272114
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity.
Geisen P; Peterson LJ; Martiniuk D; Uppal A; Saito Y; Hartnett ME
Mol Vis; 2008 Feb; 14():345-57. PubMed ID: 18334951
[TBL] [Abstract][Full Text] [Related]
19. Expression of pro- and anti-angiogenic isoforms of VEGF in the mouse model of oxygen-induced retinopathy.
Zhao M; Shi X; Liang J; Miao Y; Xie W; Zhang Y; Li X
Exp Eye Res; 2011 Dec; 93(6):921-6. PubMed ID: 22067127
[TBL] [Abstract][Full Text] [Related]
20. Celastrol inhibits pathologic neovascularization in oxygen-induced retinopathy by targeting the miR-17-5p/HIF-1α/VEGF pathway.
Zhao K; Jiang Y; Zhang J; Shi J; Zheng P; Yang C; Chen Y
Cell Cycle; 2022 Oct; 21(19):2091-2108. PubMed ID: 35695424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
